Stock News

Idera Pharmaceuticals, Inc. (IDRA) Analysts See $-0.08 EPS; QS ENERGY (QSEP) Shorts Down By 2.26%

QS ENERGY INCORPORATED (OTCMKTS:QSEP) had a decrease of 2.26% in short interest. QSEP’s SI was 90,900 shares in February as released by FINRA. Its down 2.26% from 93,000 shares previously. With 156,500 avg volume, 1 days are for QS ENERGY INCORPORATED (OTCMKTS:QSEP)’s short sellers to cover QSEP’s short positions. The stock decreased 1.79% or $0.0025 during the last trading session, reaching $0.1375. About 57,151 shares traded. QS Energy, Inc. (OTCMKTS:QSEP) has 0.00% since February 18, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts expect Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) to report $-0.08 EPS on March, 21.They anticipate $0.09 EPS change or 900.00% from last quarter’s $0.01 EPS. After having $-0.10 EPS previously, Idera Pharmaceuticals, Inc.’s analysts see -20.00% EPS growth. The stock increased 1.05% or $0.02 during the last trading session, reaching $1.93. About 1.32M shares traded. Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has risen 21.13% since February 18, 2017 and is uptrending. It has outperformed by 4.43% the S&P500.

QS Energy, Inc. develops and commercializes energy efficiency technologies. The company has market cap of $32.15 million. The companyÂ’s energy efficiency technologies assist in meeting energy demands, enhancing the economics of oil extraction and transport, and reducing greenhouse gas emissions. It currently has negative earnings. The Company’s intellectual property portfolio includes 47 domestic and international patents and patents pending, which have been developed in conjunction with and licensed from Temple University of Philadelphia, Pennsylvania.

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company has market cap of $377.58 million. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense technology. It currently has negative earnings. The company's drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis.

Investors sentiment decreased to 1.36 in Q3 2017. Its down 0.10, from 1.46 in 2017Q2. It dropped, as 5 investors sold Idera Pharmaceuticals, Inc. shares while 20 reduced holdings. 11 funds opened positions while 23 raised stakes. 46.97 million shares or 1.60% more from 46.23 million shares in 2017Q2 were reported. Moreover, Private Advisor Group Lc has 0% invested in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Tower Research Cap (Trc) owns 12,203 shares for 0% of their portfolio. Alps Advsr Inc stated it has 147,363 shares. Baker Bros Advsr Limited Partnership has invested 0.19% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Parametric Port Assoc Lc holds 0% or 11,932 shares in its portfolio. Legal And General Group Inc Public Ltd Company stated it has 29,020 shares or 0% of all its holdings. Deutsche Savings Bank Ag holds 96,675 shares or 0% of its portfolio. Guggenheim Cap Limited Com reported 0% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Financial Bank Of Mellon owns 343,188 shares or 0% of their US portfolio. Alliancebernstein L P has 0% invested in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Tci Wealth Advsrs Incorporated accumulated 0% or 2,400 shares. Lau Assocs Ltd Liability Corporation stated it has 0.03% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Nationwide Fund Advsr holds 0% or 61,173 shares. Barclays Public Limited Co invested 0% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). State Board Of Administration Of Florida Retirement holds 0% or 19,240 shares.

Among 4 analysts covering Idera Pharma (NASDAQ:IDRA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Idera Pharma had 7 analyst reports since January 6, 2016 according to SRatingsIntel. As per Wednesday, January 6, the company rating was initiated by Wedbush. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, November 16 report. The stock has “Buy” rating by Piper Jaffray on Monday, September 11. The stock of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) earned “Buy” rating by Piper Jaffray on Thursday, November 9. Wedbush maintained Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) on Wednesday, February 1 with “Outperform” rating.

Since October 26, 2017, it had 1 buy, and 2 selling transactions for $7.00 million activity. Shares for $12.00M were bought by BAKER BROS. ADVISORS LP on Thursday, October 26. On Wednesday, January 17 Pillar Invest Corp sold $480,000 worth of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) or 200,000 shares.

Leave a Reply

Your email address will not be published. Required fields are marked *